Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2022; 12(4):1557-1569. doi:10.7150/thno.69475 This issue Cite

Review

Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review

Liang Zhao1,2#, Jianhao Chen2#, Yizhen Pang1#, Kaili Fu3, Qihang Shang1, Hua Wu1, Long Sun1✉, Qin Lin2✉, Haojun Chen1✉

1. Department of Nuclear Medicine and Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen, China
2. Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China
3. Department of Oncology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China
# Contributed equally to this work

✉ Corresponding authors: Long Sun: 13178352662com. Qin Lin: linqin05com. Haojun Chen: leochen0821com; ORCID ID: 0000-0002-9101-8884.

Citation:
Zhao L, Chen J, Pang Y, Fu K, Shang Q, Wu H, Sun L, Lin Q, Chen H. Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics 2022; 12(4):1557-1569. doi:10.7150/thno.69475. https://www.thno.org/v12p1557.htm
Other styles

File import instruction

Abstract

Graphic abstract

In recent years, quinoline-based fibroblast activation protein (FAP) inhibitors (FAPI) have shown promising results in the diagnosis of cancer and several other diseases, making them the hotspot of much productive research. This review summarizes the literature for the state-of-the-art FAPI-PET imaging for cancer diagnosis compared with fluorodeoxyglucose (FDG)-PET. We also summarize the use of FAPI-PET for therapeutic regimen improvement and fibroblast activation protein (FAP)-targeted molecule modification strategies, as well as preliminary clinical studies regarding FAP-targeted radionuclide therapy. Our qualitative summary of the literature to date can inform future research directions, medical guidelines, and optimal clinical decision-making.

Keywords: cancer-associated fibroblasts (CAF), fibroblast activation protein (FAP), targeted radionuclide therapy, PET/CT, cancer management

Citation styles

APA
Zhao, L., Chen, J., Pang, Y., Fu, K., Shang, Q., Wu, H., Sun, L., Lin, Q., Chen, H. (2022). Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics, 12(4), 1557-1569. https://doi.org/10.7150/thno.69475.

ACS
Zhao, L.; Chen, J.; Pang, Y.; Fu, K.; Shang, Q.; Wu, H.; Sun, L.; Lin, Q.; Chen, H. Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics 2022, 12 (4), 1557-1569. DOI: 10.7150/thno.69475.

NLM
Zhao L, Chen J, Pang Y, Fu K, Shang Q, Wu H, Sun L, Lin Q, Chen H. Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics 2022; 12(4):1557-1569. doi:10.7150/thno.69475. https://www.thno.org/v12p1557.htm

CSE
Zhao L, Chen J, Pang Y, Fu K, Shang Q, Wu H, Sun L, Lin Q, Chen H. 2022. Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics. 12(4):1557-1569.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use